1. Home
  2. HXHX vs SNGX Comparison

HXHX vs SNGX Comparison

Compare HXHX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.50

Market Cap

6.2M

Sector

Industrials

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.38

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
SNGX
Founded
2003
1987
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.6M
IPO Year
2022
2006

Fundamental Metrics

Financial Performance
Metric
HXHX
SNGX
Price
$0.50
$0.38
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.4M
206.3K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.28
52 Week High
$1.84
$2.98

Technical Indicators

Market Signals
Indicator
HXHX
SNGX
Relative Strength Index (RSI) 48.88 49.93
Support Level $0.42 $0.35
Resistance Level $0.56 $0.42
Average True Range (ATR) 0.03 0.02
MACD -0.00 -0.00
Stochastic Oscillator 47.88 41.43

Price Performance

Historical Comparison
HXHX
SNGX

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: